Although targeting SIRT3 seems a promising new avenue in anti-cancer therapy development, more investigation is needed to ensure whether the already observed positive effects of SIRT3 positive modulators in fact occur due to a reduction in succinate levels, or if they rely on other mechanisms of action. This evidence concerns the gene SIRT3 and cancer.